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ETATE-OF-THE-ART PAPER1897In-Stent Restenosis in the DES Eraeorge D. Dangas, Bimmer E. Claessen, Adriano Caixeta, Elias A. Sanidas, Gary S. Mintz,
oxana Mehran
hile the rates of in-stent restenosis (ISR) in the initial studies of drug-eluting stents (DES)
ith simple, de novo coronary lesions were low, the rates in contemporary standard practice
ith high-risk patients and complex lesions are estimated to be 3% to 20%. Dangas and
olleagues review the biological, mechanical, and technical factors that predispose to ISR.
ntravascular imaging can assist in defining the mechanisms, but there are limited data on the
ost efficacious therapeutic strategies. This paper proposes an algorithm for the treatment of
ES ISR that may also be useful for designing the appropriate clinical trials.CLINICAL RESEARCH ARDIOVASCULAR RISK1908Higher Mortality in Diabetics With Erectile Dysfunction. David Batty, Qiang Li, Sébastien Czernichow, Bruce Neal, Sophia Zoungas, Rachel Huxley,
nushka Patel, Bastiaan E. de Galan, Mark Woodward, Pavel Hamet, Stephen B. Harrap, Neil Poulter,
ohn Chalmers, on behalf of the ADVANCE Collaborative Group
atty and colleagues studied the relationship between erectile dysfunction (ED) and
ardiovascular disease mortality in over 6,000 men with type 2 diabetes who were followed for
years. After adjusting for a range of covariates, ED at baseline was associated with an
levated risk of all cardiovascular disease events (hazard ratio [HR]: 1.19), coronary heart
isease (HR: 1.35), and cerebrovascular disease (HR: 1.36). These robust results suggest that
D is a useful marker for cardiovascular risk stratification in diabetic men.(continued on page A-20)
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iARDIAC IMAGING
1914ualitative Calcium Score From CT Attenuation Correction Scans
Correlates Well With Standard Agatston Scoresndrew J. Einstein, Lynne L. Johnson, Sabahat Bokhari, Jessica Son, Randall C. Thompson,
imothy M. Bateman, Sean W. Hayes, Daniel S. Berman
uring myocardial perfusion imaging (MPI), new hybrid systems obtain a low-dose,
onelectrocardiography-gated computed tomography (CT) scan that is used to perform
ttenuation correction (AC). Einstein and colleagues evaluated the accuracy and
eproducibility of a visual estimation of coronary artery calcium (CAC) from these scans
ompared with standard CAC Agatston scoring. Almost 500 subjects from 3 centers who
ad both MPI with AC and a standard CAC scan were studied. The amount of CAC of the
C scans was visually estimated by experienced readers on a 6-level scale. There was a high
egree of agreement between the score, with 63% in the same category and 93% within 1
ategory. CAC can be visually assessed from low-dose AC scans and may add valuable
nformation when interpreting MPI studies.RE-OPERATIVE MANAGEMENT
1922re-Procedural Beta-Blockers Are More Effective When Started
at Least 1 Week Prior to Vascular Surgeryillem-Jan Flu, Jan-Peter van Kuijk, Michel Chonchol, Tamara A. Winkel, Hence J. M. Verhagen,
eroen J. Bax, Don Poldermans
everal studies have shown beneficial effects of pre-operative -blocker (BB) therapy for
atients undergoing vascular surgery, but a large study which used a BB started the day of
urgery resulted in higher mortality. This has led to questions regarding the length of time
hat BBs should be initiated prior to surgery. Flu and colleagues reviewed data from their
nstitution, where patients are prescribed pre-operative BBs during their first pre-operative
isit; the dose is then titrated 1 week later if feasible. Treatment initiated 1 to 4 weeks or
4 weeks before surgery was associated with a lower incidence of 30-day cardiac events (odds
atios: 0.46 and 0.48, respectively) and long-term mortality (hazard ratios: 0.52 and 0.50,
espectively) compared with treatment initiated 1 week pre-operatively. These results
ndicate that BBs should be started at least 1 week prior to surgery.(continued on page A-23)
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EIOMARKERS1930Cystatin C Levels Predict Mortality in Subjects With Normal Renal Functionho-Kai Wu, Jou-Wei Lin, James L. Caffrey, Man-Huei Chang, Juey-Jen Hwang, Yu-Sheng Lin
ystatin C (Cys-C) is continually synthesized by nucleated cells, is freely filtered by the
lomerulus, is not dependent on muscle mass, and is not affected by age, giving it several
otential advantages over creatinine for measuring renal function. Wu and colleagues studied
he correlation between Cys-C levels and mortality in subjects with normal renal function,
efined as a creatinine-based estimated glomerular filtration rate (eGFR) 60 ml/min/1.73 m2.
he risk of all-cause mortality was 4.4 times higher in the highest decile of Cys-C levels
ompared with the lowest decile. The risks of cardiovascular, cancer, and noncardiovascular
ortality were all similarly higher. Serum Cys-C is prognostic of long-term mortality in
ubjects with apparently normal renal function.ditorial Comment: Horng H. Chen, p. 1937ONGENITAL VALVE DISEASE1939Low Risk of Sudden Unexpected Death After BAVP for Congenital Aortic Stenosisavid W. Brown, Amy E. Dipilato, Erin C. Chong, Kimberlee Gauvreau, Doff B. McElhinney,
teven D. Colan, James E. Lock
rown and colleagues reviewed the records of 528 subjects treated with balloon aortic
alvuloplasty (BAVP) for congenital aortic stenosis (AS) to assess the effect of exercise
estriction. During a median follow-up of 12 years (6,344 patient-years) there were only 63
eaths, and only 6 were sudden unexpected deaths (SUD). Five of these 6 deaths occurred in
ubjects 18 months of age who would not be exercising, and the other death occurred
uring sleep. SUD is extremely rare after BAVP for congenital AS, and given the low
ortality, there is no evidence to recommend exercise restriction in this cohort.
ditorial Comment: Jonathan J. Rome, p. 1947(continued on page A-24)
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ERE-CLINICAL RESEARCH1949EPO Receptor Signaling Mitigates Renal Dysfunction-Associated Heart Failuretsushi Ogino, Genzou Takemura, Masanori Kawasaki, Akiko Tsujimoto, Hiromitsu Kanamori,
onghu Li, Kazuko Goto, Rumi Maruyama, Itta Kawamura, Toshiaki Takeyama, Tomonori Kawaguchi,
akatomo Watanabe, Yoshiyuki Moriguchi, Hideki Saito, Takako Fujiwara, Hisayoshi Fujiwara,
hinya Minatoguchi
rythropoietin (EPO) is a hypoxia-induced hormone with receptors on cardiomyocytes and
ndothelial cells, suggesting that EPO exerts cardiovascular effects unrelated to hematopoiesis.
sialoerythropoietin (asialoEPO) is a derivative of EPO that does not stimulate red blood
ell production. Ogino and colleagues performed near total nephrectomies on mice, which led
o renal failure-induced cardiomyopathy. The mice were then treated with placebo,
sialoEPO, or EPO. Although only EPO relieved the anemia, both EPO and asialoEPO
educed left ventricular dilation and improved cardiac function. EPO receptor signaling exerts
irect cardioprotection in an animal model of renal dysfunction-associated heart failure.ditorial Comment: Peter van der Meer, Erik Lipsic, Dirk J. van Veldhuisen, p. 1959
